Compare · CTSO vs MMM
CTSO vs MMM
Side-by-side comparison of Cytosorbents Corporation (CTSO) and 3M Company (MMM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTSO and MMM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $80.20B, about 2782.4x CTSO ($28.8M).
- Over the past year, CTSO is down 58.5% and MMM is up 6.9% - MMM leads by 65.4 points.
- MMM has hit the wire 2 times in the past 4 weeks while CTSO has been quiet.
- MMM has more recent analyst coverage (25 ratings vs 2 for CTSO).
- Company
- Cytosorbents Corporation
- 3M Company
- Price
- $0.45-1.92%
- $153.89+0.07%
- Market cap
- $28.8M
- $80.20B
- 1M return
- -21.05%
- +7.25%
- 1Y return
- -58.53%
- +6.89%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 2
- Recent ratings
- 2
- 25
Cytosorbents Corporation
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Latest CTSO
- SEC Form 10-Q filed by Cytosorbents Corporation
- Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
- CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
- Amendment: SEC Form 10-K/A filed by Cytosorbents Corporation
- Cytosorbents Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-K filed by Cytosorbents Corporation
- Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
Latest MMM
- SEC Form SD filed by 3M Company
- 3M Announces Upcoming Investor Event
- 3M Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Sweet Thomas W was granted 1,360 shares (SEC Form 4)
- Director Kereere Suzan was granted 1,360 shares, increasing direct ownership by 27% to 6,422 units (SEC Form 4)
- Director Fitterling James R was granted 1,360 shares (SEC Form 4)
- Director Brown Thomas K was granted 1,360 shares (SEC Form 4)
- Director Chow Anne H was granted 1,360 shares (SEC Form 4)
- Director Choi Audrey was granted 1,360 shares (SEC Form 4)
- Director Bozeman David P was granted 1,360 shares (SEC Form 4)